Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRABECTEDIN vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Unresectable or metastatic liposarcoma or leiomyosarcoma after prior anthracycline-containing therapy,Metastatic soft tissue sarcoma (EU)
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
1.5 mg/m² intravenously over 24 hours every 3 weeks.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily hepatic via CYP3A4; also a substrate of P-glycoprotein.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 97-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
Volume of distribution at steady state is approximately 1000 L (>10 L/kg), indicating extensive tissue distribution and binding.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Not applicable; administered intravenously. Oral bioavailability is negligible due to extensive first-pass metabolism.
IV: 100% (only IV route); oral: not approved
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Contraindicated in patients with severe hepatic impairment (Child-Pugh C). For moderate hepatic impairment (Child-Pugh B), reduce starting dose to 0.9 mg/m². For mild hepatic impairment (Child-Pugh A), no dose adjustment but monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment recommended based on age alone; monitor renal and hepatic function due to potential age-related decline.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
Trabectedin is associated with severe and fatal neutropenic sepsis, rhabdomyolysis with renal failure, cardiotoxicity (cardiomyopathy, heart failure), hepatotoxicity, and extravasation leading to tissue necrosis. It should only be administered under the supervision of a qualified healthcare provider experienced in the use of antineoplastic agents.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Myelosuppression (neutropenia, thrombocytopenia, anemia), hepatotoxicity (elevated liver enzymes, bilirubin, hepatic failure), cardiotoxicity (LVEF decline, heart failure), rhabdomyolysis, extravasation injury, hypersensitivity reactions, and embryo-fetal toxicity.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to trabectedin or any of its excipients, concomitant use with yellow fever vaccine, severe hepatic impairment.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Grapefruit and grapefruit juice should be avoided as they may increase trabectedin levels. There are no other specific dietary restrictions.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Trabectedin is teratogenic based on animal studies. It is contraindicated in pregnancy. First trimester exposure carries high risk of major malformations and pregnancy loss. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Effective contraception is required during treatment and for at least 3 months after the last dose.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Unknown if trabectedin is excreted in human milk; however, due to potential serious adverse reactions in breastfeeding infants, women should discontinue breastfeeding during treatment and for at least 3 weeks after the last dose. M/P ratio is not available.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No clinical data are available for dose adjustments during pregnancy. Trabec... is contraindicated in pregnancy; therefore, no dose adjustment is recommended. If inadvertent exposure occurs, immediate discontinuation and supportive care are advised.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Trabectedin is a marine-derived alkylating agent indicated for advanced soft tissue sarcoma (STS) and relapsed platinum-sensitive ovarian cancer. It requires dexamethasone premedication to reduce hepatotoxicity. Monitor liver function tests (LFTs) closely; dose reduction or interruption is needed for transaminase elevation. Administer via central line due to vesicant properties. Consider cardiac monitoring as QT prolongation can occur. Use with caution in patients with hepatic impairment.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
This medication is given intravenously over 24 hours through a central line.,You will receive dexamethasone before each infusion to help prevent liver side effects.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe fatigue.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not breastfeed during treatment and for 3 months after the last dose.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
"Trabectedin, a potent anticancer agent, inhibits the cytochrome P450 (CYP) enzyme CYP3A4, which is primarily responsible for the metabolism of cyclosporine. When co-administered, trabectedin decreases the clearance of cyclosporine, leading to significantly elevated cyclosporine blood concentrations. This increased exposure raises the risk of cyclosporine-related toxicities, particularly nephrotoxicity, hepatotoxicity, and immunosuppression-related complications, potentially requiring dose adjustments and close monitoring."
"Nilotinib is primarily metabolized by CYP3A4, and trabectedin is a moderate inhibitor of CYP3A4. Concomitant use may increase nilotinib exposure, leading to elevated plasma concentrations and a higher risk of QT prolongation, torsade de pointes, and sudden cardiac death. This interaction requires cautious monitoring and potential dose adjustment."
"Trabectedin, an alkylating agent used for soft tissue sarcoma, is metabolized primarily by CYP3A4. Posaconazole, a potent CYP3A4 inhibitor, can significantly increase trabectedin exposure by reducing its clearance. This elevated concentration may enhance trabectedin-induced hepatotoxicity and myelosuppression, increasing the risk of severe adverse effects such as elevated liver enzymes and febrile neutropenia."
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRABECTEDIN vs CLOFARABINE, answered by our medical review team.
TRABECTEDIN is a Antineoplastic Agent that works by Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRABECTEDIN and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRABECTEDIN is: 1.5 mg/m² intravenously over 24 hours every 3 weeks.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRABECTEDIN and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRABECTEDIN is classified as Category C. Trabectedin is teratogenic based on animal studies. It is contraindicated in pregnancy. First trimester exposure carries high risk of major malformations and pregnancy loss. Second. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.